MYELOID CELL NEOPLASM CLASSIFICATION

WHO classification of myeloid neoplasms and acute leukemia 

(The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia Blood 2009)

1. Myeloproliferative neoplasms (MPN)
2. Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1
3. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
4. Myelodysplastic syndrome (MDS)
5. Acute myeloid leukemia and related neoplasms
6. Acute leukemias of ambiguous lineage
7. B lymphoblastic leukemia/lymphoma
8. T lymphoblastic leukemia/lymphoma 

1. MPN
  1. Chronic myelogenous leukemia, BCR-ABL1–positive (CML)
  2. Chronic neutrophilic leukemia (CNL)
  3. Polycythemia vera
  4. Primary myelofibrosis
  5. Essential thrombocythemia
  6. Chronic eosinophilic leukemia, not otherwise specified  (CEL)
  7. Mastocytosis
  8. Myeloproliferative neoplasms, unclassifiable

PCRV
Primary Myelofibrosis
Essential Thrombocythemia
Additional References


4. MDS: TYPE (Table 2 of WHO Classification) - IPSS Score - IPSS Risk Group - Performance Status 
Asymptomatic / Symptomatic 
  • Anemia:
  • Thrombocytopenia:
  • Neutropenia with recurrent Infection:
Immunization Status:
Case 27-2010 (Classification MDS/AML)
The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia Blood 2009
IPSS MDS Up-To-Date    (IPSS Calculator: Up-To-Date)
IPSS-R MDS Up-To-Date (IPSS R Calculator Up-To-Date)
Eastern Cooperative Oncology Group (ECOG, Zubrod, WHO) performance scale Up-To-Date 
Karnofsky performance status scale Up-to-Date
Overview of the treatment of myelodysplastic syndromes Up-To-Date
MDS references
Myelodysplastic syndromes Lancet 2014
Myelodysplastic Syndromes NEJM 2009
How I treat patients with myelodysplastic syndromes Blood 2009
How we treat lower-risk myelodysplastic syndromes. Blood 2013
How we treat higher-risk myelodysplastic syndromes Blood 2014

5. AML: 


  1. Acute myeloid leukemia with recurrent genetic abnormalities
    • AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
    • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 APL with t(15;17)(q22;q12); PML-RARA
    • AML with t(9;11)(p22;q23); MLLT3-MLL
    • AML with t(6;9)(p23;q34); DEK-NUP214
    • AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
    • AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
    • Provisional entity: AML with mutated NPM1
    • Provisional entity: AML with mutated CEBPA restricted to balletic mutation
  2. Acute myeloid leukemia with myelodysplasia-related changes 
  3. Therapy-related myeloid neoplasms
    • 2 types 
      • Drugs targeting topoisomerase II like anthracyclines, epipodophylotoxins (within months to 2 years of exposure)
      • Alkylating agent (5-6 years after exposure)
  4. Acute myeloid leukemia, not otherwise specified
    • AML with minimal differentiation
    • AML without maturation
    • AML with maturation
    • Acute myelomonocytic leukemia
    • Acute monoblastic/monocytic leukemia 
    • Acute erythroid leukemia
      • Pure erythroid leukemia
      • Erythroleukemia, erythroid/myeloid 
    • Acute megakaryoblastic leukemia 
    • Acute basophilic leukemia
    • Acute panmyelosis with myelofibrosis
  5. Myeloid sarcoma
  6. Myeloid proliferations related to Down syndrome
    • Transient abnormal myelopoiesis
    • Myeloid leukemia associated with Down syndrome
  7.  Blastic plasmacytoid dendritic cell neoplasm
Comments